SEC Form 4 · accession 0001214659-18-003059
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP, Chief Scientific Officer
Period of report
Mar 9, 2018
Accepted (ET)
Apr 26, 2018 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 9, 2018 | M | 7,000 | $17.41 | A | 9,877 | D | |
| Common Stock | Mar 9, 2018 | M | 7,500 | $21.51 | A | 17,377 | D | |
| Common Stock | Mar 9, 2018 | M | 7,500 | $24.99 | A | 24,877 | D | |
| Common StockF2 | Mar 9, 2018 | S | 22,000 | $33.0018 | D | 2,877 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $17.41 | Mar 9, 2018 | M | 7,000 | D | — | May 20, 2024 | Common Stock | 7,000 | 18,936 | D |
| Employee Stock Option (Right to Buy)F3 | $21.51 | Mar 9, 2018 | M | 7,500 | D | — | Feb 3, 2025 | Common Stock | 7,500 | 15,000 | D |
| Employee Stock Option (Right to Buy)F3 | $24.99 | Mar 9, 2018 | M | 7,500 | D | — | Jan 21, 2026 | Common Stock | 7,500 | 45,000 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $33.00 to $33.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to
- F31/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter